Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
D 10.38 -2.54% -0.27
FOLD closed down 2.54 percent on Friday, July 19, 2024, on 75 percent of normal volume.
Earnings due: Aug 6
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish -2.54%
Pocket Pivot Bullish Swing Setup -2.54%
Upper Bollinger Band Walk Strength -2.54%
Overbought Stochastic Strength -2.54%
Overbought Stochastic Strength -2.08%
Upper Bollinger Band Touch Strength -2.08%
Gapped Down Weakness -2.08%
Pocket Pivot Bullish Swing Setup -4.24%
BB Squeeze Ended Range Expansion -4.24%
Above Upper BB Strength -4.24%

   Recent Intraday Alerts

Alert Time
Down 2 % about 5 hours ago
60 Minute Opening Range Breakdown about 5 hours ago
Fell Below Previous Day's Low about 5 hours ago
10 DMA Support about 7 hours ago
Fell Below 10 DMA about 7 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amicus Therapeutics, Inc. Description

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Orphan Drug Lipid Storage Disorders Inborn Errors Of Metabolism Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disorder Orphan Disease Pompe Disease Gaucher Disease Lysosomal Storage Disorders Rare And Orphan Diseases Treatment Of Pompe Disease

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.57
52 Week Low 9.02
Average Volume 2,401,932
200-Day Moving Average 11.38
50-Day Moving Average 9.99
20-Day Moving Average 10.19
10-Day Moving Average 10.48
Average True Range 0.32
RSI (14) 53.05
ADX 13.81
+DI 26.02
-DI 20.97
Chandelier Exit (Long, 3 ATRs) 9.98
Chandelier Exit (Short, 3 ATRs) 10.52
Upper Bollinger Bands 10.85
Lower Bollinger Band 9.53
Percent B (%b) 0.64
BandWidth 12.98
MACD Line 0.15
MACD Signal Line 0.10
MACD Histogram 0.0476
Fundamentals Value
Market Cap 3.04 Billion
Num Shares 293 Million
EPS -0.59
Price-to-Earnings (P/E) Ratio -17.59
Price-to-Sales 10.67
Price-to-Book 29.84
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.85
Resistance 3 (R3) 10.89 10.79 10.77
Resistance 2 (R2) 10.79 10.67 10.76 10.74
Resistance 1 (R1) 10.58 10.60 10.53 10.54 10.72
Pivot Point 10.48 10.48 10.45 10.45 10.48
Support 1 (S1) 10.27 10.36 10.22 10.23 10.04
Support 2 (S2) 10.17 10.29 10.14 10.02
Support 3 (S3) 9.96 10.17 9.99
Support 4 (S4) 9.92